Incidence Rate of Abortions Reduced During COVID-19 Pandemic
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 23, 2023 -- The incidence rate of abortions decreased during the COVID-19 pandemic, mainly driven by procedural abortions, according to a study published online Oct. 24 in the Annals of Internal Medicine.
Catherine S. Hwang, M.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues estimated changes in the incidence rate of induced medical and procedural abortions in a cross-sectional study involving reproductive-aged commercially insured women in the United States. The monthly age-adjusted incidence rates were measured among women aged 15 to 44 years from January 2018 to June 2022.
The researchers found that the estimated age-adjusted monthly incidence rate of abortions was 151 per million women in January 2018, with equal rates of medical and procedural abortions. An immediate 14 percent decrease was seen in the monthly incidence rate of abortions after March 2020 (21 per million women), driven by a 31 percent decline in procedural abortions (22 per million women). Of the medical abortions, fewer than 4 percent each month were administered by telehealth.
"Our findings suggest that expanded commercial insurance coverage for telehealth abortions could provide an important opportunity to expand access to abortion care, particularly as some states restrict the delivery of abortion services," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
Residual Risk Seen for Death, Postacute Sequelae in Third Year After COVID-19 Hospitalization
THURSDAY, June 13, 2024 -- For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19...
Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...
Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
MONDAY, June 10, 2024 -- A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.